
-
Insmed Incorporated NasdaqGS:INSM Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Location: 700 US Highway 202/206, Bridgewater, NJ, 08807, United States | Website: https://www.insmed.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
12.71B
Cash
1.199B
Avg Qtr Burn
-190.5M
Short % of Float
9.98%
Insider Ownership
0.82%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ARIKAYCE (Amikacin Liposome Inhalation Suspension) Details Mycobacterium avium complex lung disease, Nontuberculous mycobacterial lung disease | Approved Update | |
Brensocatib Details Non-Cystic Fibrosis Bronchiectasis | PDUFA Approval decision | |
ARIKAYCE (Amikacin Liposome Inhalation Suspension) Details Mycobacterium avium complex lung disease, Nontuberculous mycobacterial lung disease | Phase 3 Data readout | |
TPIP (Treprostinil Palmitil Inhalation Powder) Details Pulmonary hypertension, Interstitial lung disease | Phase 3 Initiation | |
TPIP (Treprostinil Palmitil Inhalation Powder) Details Pulmonary arterial hypertension Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
Brensocatib (DPP1 inhibitor) Details Chronic rhinosinusitis | Phase 2 Data readout | |
Brensocatib (DPP1 inhibitor) Details Cystic fibrosis | Phase 2 Update |